

Systematic review and meta-analysis of the prevalence of common respiratory viruses in children < 2 years with bronchiolitis reveal a weak role played by the SARS-CoV-2

Sebastien Kenmoe¹, Cyprien Kengne-Nde², Jean Thierry Ebogo-Belobo³, Donatien Serge Mbaga⁴, Abdou Fatawou Modiyinji^{1,5}, Richard Njouom^{1*}

1: Department of Virology, Centre Pasteur of Cameroon, 451 Rue 2005, P.O. Box 1274 Yaoundé, Cameroon

2: National AIDS Control Committee, Epidemiological Surveillance, Evaluation and Research Unit, P.O. Box 1459 Yaounde, Cameroon

3: Medical Research Centre, Institut of Medical Research and Medicinal Plants Studies, Yaoundé, Cameroon

4: Department of Microbiology, Faculty of Science, The University of Yaounde I, Yaoundé, Cameroon

5: Department of Animals Biology and Physiology, Faculty of Sciences, University of Yaoundé I, P.O. Box 337, Yaoundé, Cameroon

* Correspondence to: Richard Njouom, PhD/HDR

Centre Pasteur of Cameroon, P.O Box: 1274 Yaoundé

Email: njouom@pasteur-yaounde.org / njouom@yahoo.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Telephone: Office: (00237) 222 23 10 15 and mobile: (00237) 699 65 47 67

Abstract

Introduction The advent of genome amplification assays has allowed description of new respiratory viruses and to reconsider the role played by certain respiratory viruses in bronchiolitis. This systematic review and meta-analysis was initiated to clarify the prevalence of respiratory viruses in children with bronchiolitis in the coronavirus disease 2019 pandemic context.

Methods We performed an electronic search through Pubmed and Global Index Medicus databases. We included observational studies reporting the detection rate of common respiratory viruses in children with bronchiolitis using molecular assays. Data was extracted and the quality of the included articles was assessed. We conducted sensitivity, subgroups, publication bias, and heterogeneity analyses using a random effect model.

Results The final meta-analysis included 51 studies. Human respiratory syncytial virus (HRSV) was largely the most commonly detected virus 59.2%; 95% CI [54.7; 63.6]). The second predominant virus was Rhinovirus (RV) 19.3%; 95% CI [16.7; 22.0]) followed by Human bocavirus (HBoV) 8.2%; 95% CI [5.7; 11.2]). Other reported viruses included Human Adenovirus (HAdV) 6.1%; 95% CI [4.4; 8.0]), Human Metapneumovirus (HMPV) 5.4%; 95% CI [4.4; 6.4]), Human Parainfluenzavirus (HPIV) 5.4%; 95% CI [3.8; 7.3]), Influenza 3.2%; 95% CI [2.2; 4.3], mild Human Coronavirus (HCoV) 2.9%; 95% CI [2.0; 4.0]), and Enterovirus (EV) 2.9%; 95% CI [1.6; 4.5]). HRSV was the predominant virus involved in multiple detection

and most codetections were HRSV + RV 7.1%, 95% CI [4.6; 9.9]) and HRSV + HBoV 4.5%, 95% CI [2.4; 7.3]).

Conclusions The present study has shown that HRSV is the main cause of bronchiolitis in children, we also have Rhinovirus, and Bocavirus which also play a significant role. No study has reported the presence of Severe Acute Respiratory Syndrome Coronavirus-2 in children with bronchiolitis to date.

Review registration PROSPERO, CRD42018116067.

Keywords Respiratory viruses; Acute Bronchiolitis; Children

1 **Introduction**

2

3 Bronchiolitis infection is included among the leading cause of hospitalization and death in
4 pediatrics.¹⁻⁵ Bronchiolitis also represents a high economic burden on society and has generated
5 a high hospital cost of around 72 million euros for children under the age of 2 in Portugal
6 between 2000 and 2015.³ A study by Shi et al. found that lower respiratory infections due to
7 Human Respiratory Syncytial Virus (HRSV), which is the main agent of bronchiolitis, causes
8 approximately 3.2 million hospitalizations and about 60 thousand deaths per year worldwide in
9 children under the age of 5.⁶

10 Bronchiolitis is generally considered to be a viral illness, and the most common include HRSV,
11 Influenza virus, Rhinovirus (RV), Human Metapneumovirus (HMPV), Enterovirus (EV),
12 Human Coronavirus (HCoV), Human Parainfluenza Virus (HPIV), Human Adenovirus
13 (HAdV), and Human Bocavirus (HBoV).

14 During the last two decades, the increase in use of Polymerase Chain Reaction (PCR) assays
15 for the detection of respiratory viruses has led to a reassessment of the role played by viruses
16 such as RV in acute respiratory infections.^{7,8} These molecular detection assays have also
17 revealed new respiratory viruses such as HMPV and HBoV, and some RV and HCOV species.⁹⁻

18 ¹³ Coronavirus disease 2019 (Covid-19) was first reported in Wuhan, Hubei province in
19 China ¹⁴. This disease is caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-
20 CoV-2). This virus is the seventh described species of human coronavirus which includes 4
21 species associated with mild diseases (HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-
22 HKU1) and 3 species associated with severe pneumonia (SARS-CoV, MERS-CoV and SARS-
23 CoV-2) ¹⁴⁻²⁰. The World Health Organization declared Covid-19 as a public health emergency
24 of international concern on January 30, 2020 and as a global pandemic on March 11, 2020.

25 Covid-19 spread rapidly worldwide and is now present in 188 countries in the 5 continents. At
26 August 22, 2020, more than 20 million of cases have been confirmed and about 800 thousand
27 deaths due to Covid-19 were recorded ²¹. The objective of this study was to report the detection
28 rate of viral agents using PCR and the associated risk factors with bronchiolitis in children ≤ 2
29 years in the era of Covid-19.

30

31 **Methods**

32

33 **Study design**

34 This systematic review was conducted according to the principles of the Centre for Reviews
35 and Dissemination.²² The methodological standards of the PRISMA declaration have been
36 applied for this review (S1 Table).²³ The protocol for this review has been registered in the
37 PROSPERO database under number CRD42018116067. This review reports previous
38 published data and ethical clearance was not required.

39

40 **Electronic search**

41 Pubmed and Global Index Medicus were searched with a combination of keywords related to
42 common respiratory viruses and bronchiolitis. The search strategy applied in Pubmed is
43 available in S2 Table. The search strategy in Pubmed has been adjusted to the Global Index
44 Medicus database. The databases have been consulted since their creation until 06 February
45 2019 and updated on 16 August 2020.

46

47 **Manual search**

48 The literature search was supplemented by a review of references of included articles and
49 relevant reviews. We have gradually updated our search strategy iteratively by adding the
50 specific keywords of the searches found manually. No language or geographical restrictions
51 have been applied.

52

53 **Integration criteria**

54 Observational studies (cohort, case-control, and cross-sectional) published in peer-reviewed
55 journals were used if they reported the detection of respiratory viruses using PCR assays in
56 children < 2 years with bronchiolitis. A wide range of definition of bronchiolitis has been used
57 by the authors of the included articles. Case reports, review, and duplicated studies were
58 excluded.

59

60 **Study selection**

61 Two investigators (SK and AFM) independently preselected the identified articles on the basis
62 of their titles and abstracts (if necessary). The relevance of eligible studies was assessed using
63 predefined integration criteria.

64

65 **Data extraction**

66 Data from the included studies were independently extracted by two authors (SK and FBSN)
67 via a preconceived form. The information gathered included: the name of the author, the year
68 of publication, the design of the study, the country, the WHO regions, the sampling method,
69 the period of the study, the definition of bronchiolitis, the exclusion criteria, the sample type,
70 the viral detection assay, age range, mean or median age, percentage of male gender, number
71 of samples tested for each virus, number of positives for each virus, and the data of the
72 evaluation of the study quality. All disagreements were resolved by discussion between two
73 authors and an arbitration by a third author if need be.

74

75 **Assessing research quality**

76 The quality of the studies was estimated as low (8-10), moderate (5-7), and high (0-4) risk of
77 bias using the Hoy et al. assessment tool (S3 Table).²⁴

78

79 **Data synthesis**

80 Forest plots, summary tables and a narrative summary were used to present the overall results.
81 The calculation of the prevalence took into account the weight of each study. Each prevalence
82 was estimated using a random-effect meta-analysis given the inseparable heterogeneity of
83 observational studies. A dual arcsine transformation of Freeman-Turkey was used to stabilize
84 the variances in the prevalence calculation. Subgroup analysis was performed to estimate
85 prevalence variations by sample type used for viral detection, WHO region and some viral
86 codetection status. The Cochran Q test and the I^2 statistic were used to measure heterogeneity
87 between studies.²⁵ Analysis based on studies with a low risk of bias, children ≤ 1 year,
88 hospitalized children, and cross sectional were used for sensitivity analyses. Visual inspection
89 of a funnel plot and the Egger test were used to estimate the risk of publication bias.²⁶ A
90 prediction interval was provided for all meta-analyses to predict future study values. Values of
91 $p < 0.05$ were assimilated as statistically significant. The analyses were conducted using the
92 meta package version 4.9-2 under the R version 3.5.1 software.^{27,28} The code "metaprop" was
93 used for meta-analyses of prevalence.

94 **Results**

95 **Study selection and characteristics**

96 The literature search provided a total of 3777 articles and 154 duplicates were excluded.
97 Selection based on titles and abstracts excluded 3370 irrelevant articles. We therefore examined
98 253 complete texts and excluded 203 for multiple reasons (Fig 1, S4 Table). We finally stayed
99 with 50 articles (51 studies) that met the inclusion criteria.²⁹⁻⁷⁸ The different bronchiolitis case
100 definitions are showed in the S5 Table. Children were recruited in included studies between
101 October 1999 and December 2017 (Table 1). The selected studies were published between 2002
102 and 2020. Almost all children included in these studies were recruited consecutively. Most
103 studies were cross-sectional studies (44; 86.3%), published in the English language (44; 86.3),
104 carried out in Europe (28; 54.9%), carried out on a continuous period (35; 68.6%). Most studies
105 had a prospective recruitment (44; 86.3%), a clear bronchiolitis case definition (45; 88.2%),
106 and low risk of bias (34; 66.7%). Hospitalized boys less than 2 years were predominant in
107 included studies. Analyzed samples were mainly nasopharyngeal secretions (45; 88.2%).

108

109 **Fig 1.** Flow chart of research and selection of studies

110

111 **Table 1. Sociodemographic and clinical characteristics of included studies**

Characteristics	N = 51	%
% Male; range	48.0-72.5	
Age range		
• < 0.5 year	2	3.9

• < 1 Year	17	33.3
• < 1.5 years	3	5.9
• < 2 Years	28	54.9
• Unclear/Not reported	1	2.0
Period of inclusion of participants; range	Oct/1999-Dec/2017	
Year of publication; range	2002-2020	
Study design		
• Case control	2	3.9
• Cohort (Baseline data)	5	9.8
• Cross sectional	44	86.3
Sampling		
• Consecutive sampling	50	98.0
• Simple random sampling	1	2.0
Timing of data collection		
• Prospectively	44	86.3
• Retrospectively	7	13.7
Study bias		
• Low risk of bias	34	66.7
• Moderate risk of bias	17	33.3
Seasonality		

• Continuous study period	35	68.6
• Interrupted time series study	15	29.4
• Unclear/Not reported	1	2.0
WHO region		
• America	12	23.5
• Eastern Mediterranean	3	5.8
• Europe	28	54.9
• South-East Asia	1	1.9
• Western Pacific	7	13.7
Language		
• English	44	86.3
• Non english	7	13.7
Hospitalization		
• Hospitalized	40	78.4
• Hospitalized/Outpatients	4	7.8
• Outpatients	5	9.8
• Unclear/Not reported	2	3.9
Bronchiolitis definition		
• No	6	11.8

• Yes	45	88.2
Sample type		
• Nasal secretions	5	9.8
• Nasopharyngeal secretions	45	88.2
• Throat secretions	1	2.0

112

113 **Prevalence and codetection rate of viral infections among children < 2 years with**
 114 **bronchiolitis**

115

116 HRSV was largely the most commonly detected virus (59.2%; 95% CI [54.7; 63.6]). Other
 117 viruses included in descending order: RV (19.3%; 95% CI [16.7; 22.0]), HBoV (8.2%; 95% CI
 118 [5.7; 11.2]), HAdV (6.1%; 95% CI [4.4; 8.0]), HPIV (5.4%; 95% CI [3.8; 7.3]), HMPV (5.4%;
 119 95% CI [4.4; 6.4]), Influenza (3.2%; 95% CI [2.2; 4.3]), mild HCoV (2.9%; 95% CI [2.0; 4.0]),
 120 and EV (2.9%; 95% CI [1.6; 4.5]) (Fig 2, S1 Fig). HRSV was the predominant virus involved
 121 in multiple detections. The most codetections were HRSV + RV (7.1%, 95% CI [4.6; 9.9]) and
 122 HRSV + HBoV (4.5%, 95% CI [2.4; 7.3]) (S2 Fig). We did not find any major change in our
 123 results when we conducted sensitivity analyses that included only children < 1 year,
 124 hospitalized children, studies with bronchiolitis case definition, cross sectional studies, and low
 125 risk of bias studies (S6 Table). Substantial heterogeneity was detected in overall prevalence and
 126 sensitivity analyses for all viruses. Publication bias was detected for HMPV and Influenza meta-
 127 analyses (S6 Table and S3-11 Fig).

128

129 **Fig 2.** Global prevalence of Respiratory Viruses in children with bronchiolitis

130

131 **Subgroup meta-analysis**

132 The subgroup analysis showed a significant difference in the prevalence of HRSV ($p < 0.001$),
133 RV ($p < 0.001$), HBoV ($p < 0.001$), HAdV ($p < 0.001$), HPIV ($p < 0.001$), mild HCoV ($p <$
134 0.001), and EV ($p < 0.001$) according to the WHO regions (S7 Table). Lower prevalence was
135 observed in Eastern Mediterranean for HRSV, HBoV, and EV; in America for RV and HAdV;
136 and in Europe for HPIV. A significant increase in the prevalence was observed for continuous
137 study period for HMPV ($p = 0.005$), HPIV ($p = 0.005$), and Influenza ($p = 0.014$). The subgroup
138 analysis according to the type of sample revealed a significant increase in nasopharyngeal
139 secretions for HRSV ($p < 0.001$).

140

141 **Discussion**

142

143 This systematic review asserts the strong predominance of HRSV in children < 2 years with
144 bronchiolitis. We have shown that HRSV is present in almost two-thirds of bronchiolitis
145 cases. RV and two recently described viruses by the advent of molecular assays (HBoV and
146 HMPV) were among the most common viruses. The HRSV + RV and HRSV + HBoV co-
147 detections were the most frequent.

148

149 The predominance pattern of respiratory viruses in bronchiolitis reported in this study is
150 consistent with that reported by several previous narrative reviews.^{79–81} Regardless of multiple
151 factors including detection assays, tested sample types, children's age, and infection severity

152 most studies report that HRSV is the major agent in cases of bronchiolitis with rates ranging
153 from 50 to 80%.⁸⁰ RV, that is the second most common virus in this study, has long been
154 considered a cause of benign respiratory infection such as the common cold.⁸² Early
155 investigations of the prevalence of RV in bronchiolitis episodes were conducted using
156 traditional assays including serological testing and culture.^{83,84} The development of serological
157 assays has always been difficult for RV because of the high number of serotypes. It is also well
158 known that RV is insensitive to most cell lines used in viral isolation.^{85,86} Therefore the recent
159 widespread use of PCR that would be linked to evidence of this importance of RV in low
160 respiratory tract infections.⁸⁷⁻⁹² Many other recent works have also highlighted the importance
161 of RV in other respiratory infections such as asthma, wheezing, and long-term respiratory
162 sequelae in pre-school children.⁹³⁻⁹⁸

163
164 HMPV and HBoV were first described in 2001 and 2005 respectively using molecular
165 assays.^{9,12} As previously reported, our study further reinforces the role assigned to these
166 relatively new agents in bronchiolitis.⁷⁹⁻⁸¹ Human Bocavirus is commonly reported in
167 asymptomatic children and in co-detection with other viruses, which has long raised the
168 question of its exclusive involvement in the pathogenesis of respiratory infections.⁹⁹⁻¹⁰⁴ On the
169 other hand, reports have also highlighted HBoV involvement in life-threatening in children with
170 severe respiratory infections, but this still does not establish a role for bocavirus as an important
171 pathogen.^{105,106} The HBoV reported in this study as the third most common virus in children
172 with bronchiolitis therefore deserves further investigation to explain its clinical relevance in
173 bronchiolitis.

174
175 This study has shown an increased codetection of either RV or HBoV in children infected with
176 HRSV. This high prevalence of RV or HBoV in HRSV positive patients may indicate an

177 overlap in the circulation period of these predominant viruses in bronchiolitis. It is known that
178 HBoV and RV are recorded throughout the year, which obviously coincides with the circulation
179 period of HRSV with peaks in winter and early spring. ^{107,108}

180

181 Respiratory viruses are characterized by their easy transmission through the contact of
182 contaminated objects and through the airway. ^{109–111} These viruses are thus cosmopolitan and
183 know no boundaries in their distribution across the different regions of the world. The
184 frequencies of detection of respiratory viruses throughout the various regions of the world are
185 governed by multiple climatic, sociodemographic and cultural factors. We are therefore unable
186 to interpret the pattern of dominance observed in the prevalence of respiratory viruses according
187 to the WHO regions observed during this work. The majority of interrupted time series studies
188 included in this review were conducted in the HRSV peak circulation period. ¹¹² Contrary to
189 our expectations, the prevalence of HRSV in these interrupted time series studies was not
190 significantly greater than studies conducted over a continuous period. On the other hand, the
191 HMPV, the HPIV and Influenza presented a significant higher prevalence in studies performed
192 in continuous period. This result suggests that the peaks of circulation of HMPV, HPIV and
193 Influenza are different from that of HRSV. In fact the frequency of detection of respiratory
194 viruses can vary from year to another. Some studies have shown an overlap of HRSV and
195 HMPV circulation while others have not. ^{113,114} This disagreement observed in the seasonal
196 pattern of these respiratory viruses circulation compromises our ability to interpret our subgroup
197 analysis according to the continuous or interrupted study period.

198

199 It is generally recognized that bronchiolitis is a respiratory condition of children up to the age
200 of 2 years. ¹¹⁵ Several reports have shown that only clinical symptoms are enough for the

201 management of children with bronchiolitis, and viral testing is generally considered
202 unnecessary.^{116,117} Data on the impact of multiple viral infections on the severity of
203 bronchiolitis is controversial and does not justify recommendations of routinely virological
204 examinations in most guidelines.^{118,119} Increase use of health resources and regularly recorded
205 codetections do not warrant cohorting of infected children and is another reason that hinder the
206 investigation of viral pathogens in bronchiolitis clinical practice.¹¹⁷ However, virological tests
207 are still used in children with severe bronchiolitis to reduce the unnecessary use of antibiotics
208 and interventions such as chest X-rays.^{115,120} In children admitted to receive palivizumab,
209 American Academy of Pediatrics recommends HRSV testing for cessation of treatment if the
210 test is positive.¹²¹ Assessing the respective contribution of respiratory viruses in bronchiolitis,
211 a crucial importance in the orientation of priority actions specific to the choice of viruses in
212 public health, particularly with the imminent introduction of vaccines against some respiratory
213 viruses, especially HRSV.¹²²

214

215 It is important to mention that the small number of studies in some subgroups analyses restricts
216 our ability to draw definitive conclusions. A second limitation in our study is that we did not
217 consider multiple other factors that could further explain the variability in the prevalence of
218 viruses in bronchiolitis such as comorbidities, anti-HRSV prophylaxis and the number of virus
219 types sought in studies for multi-species such as mild HCoV and HPIV. It is also known that
220 bronchiolitis case definitions show great variability in terms of age limit and constellation of
221 clinical symptoms according to geographic area and time that we did not consider in this study.

222 ^{79,123}

223

224 Beyond these limitations, this systematic review and meta-analysis reports the prevalence
225 recorded over two decades of a large panel of common respiratory viruses currently involved

226 in bronchiolitis. We report the data obtained in almost all WHO regions from the PCR that
227 currently represent the most commonly used assays in diagnosing respiratory viruses, which is
228 another major asset of this work. We also have conducted multiple sensitivity analyses that
229 further strengthen the robustness of our results on multiple important aspects such as children
230 hospitalization, age range, and design and quality of studies.

231

232 The results of this systematic review and meta-analysis further underline the strong majority of
233 HRSV in children with bronchiolitis. This work also highlights the importance of RV and the
234 newly described HMPV and HBoV in children with bronchiolitis. The HRSV + RV and HRSV
235 + HBoV co-detections were the most frequent in children with bronchiolitis.

236

237 The high costs of prophylaxis with palivizumab remain a major wall to its widespread use in
238 reducing the burden of bronchiolitis in children. Therefore, to significantly reduce the heavy
239 burden of bronchiolitis due to HRSV in children, the finalization and availability of HRSV
240 vaccines is a high priority. Future studies should explore the involvement of multiple viral
241 infections in the severity of bronchiolitis cases to finally bring down the iron curtain on the
242 need for the use of virologic testing in clinical practice for the better management of children
243 with bronchiolitis. Studies are also needed to clarify the clinical impact of HBoV in
244 bronchiolitis cases.

245

246 **Legends**

247 **Table 1.** General characteristics of included studies

248 **Fig 1.** Flow chart of research and selection of studies

249 **Fig 2.** Global prevalence of Respiratory Viruses in children < 2 years with bronchiolitis

250

251 **Supporting information**

252 S1 Table. Preferred reporting items for systematic reviews and meta-analyses checklist

253 S2 Table. Search strategy in Medline (Pubmed)

254 S3 Table. Items for risk of bias assessment

255 S4 Table. Main reasons of exclusion of eligible studies

256 S5 Table. Individual characteristics of included studies

257 S6 Table. Global prevalence and sensitivity analyses of respiratory viral infections in children
258 < 2 years with bronchiolitis

259 S7 Table. Subgroup prevalence of respiratory viral infections in children with acute
260 bronchiolitis

261 S1 Fig. Global prevalence of Respiratory Viruses in children < 2 years with bronchiolitis

262 S2 Fig. Codetection rate of viral infections among children < 2 years with bronchiolitis

263 S3 Fig. Funnel plot for publication for HRSV in people with bronchiolitis

264 S4 Fig. Funnel plot for publication for RV in people with bronchiolitis

265 S5 Fig. Funnel plot for publication for HBoV in people with bronchiolitis

266 S6 Fig. Funnel plot for publication for HAdV in people with bronchiolitis

267 S7 Fig. Funnel plot for publication for HMPV in people with bronchiolitis

268 S8 Fig. Funnel plot for publication for HPIV in people with bronchiolitis

269 S9 Fig. Funnel plot for publication for Influenza in people with bronchiolitis

270 S10 Fig. Funnel plot for publication for EV in people with bronchiolitis

271 S11 Fig. Funnel plot for publication for HCoV in people with bronchiolitis

272

273 **Acknowledgments** None

274

275 **References**

276

- 277 1. Deshpande S, Northern V. The clinical and health economic burden of respiratory
278 syncytial virus disease among children under 2 years of age in a defined geographical area.
279 Arch Dis Child 2003;88:1065-1069.
- 280 2. Hervás D, Reina J, Yañez A, del Valle JM, Figuerola J, Hervás JA. Epidemiology of
281 hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV
282 bronchiolitis. Eur J Clin Microbiol Infect Dis 2012;31:1975-1981.
- 283 3. Mendes-da-Silva A, Gonçalves-Pinho M, Freitas A, Azevedo I. Trends in hospitalization
284 for acute bronchiolitis in Portugal: 2000-2015. Pulmonology June 2018.
- 285 4. Schuh S, Kwong JC, Holder L, Graves E, Macdonald EM, Finkelstein Y. Predictors of
286 Critical Care and Mortality in Bronchiolitis after Emergency Department Discharge. The
287 Journal of Pediatrics 2018;199:217-222.e1.
- 288 5. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated
289 mortality and estimates of respiratory syncytial virus-associated deaths among US
290 children, 1979-1997. J Infect Dis 2001;183:16-22.
- 291 6. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden
292 estimates of acute lower respiratory infections due to respiratory syncytial virus in young
293 children in 2015: a systematic review and modelling study. Lancet July 2017.
- 294 7. Gern JE. The ABCs of Rhinoviruses, Wheezing, and Asthma. Journal of Virology
295 2010;84:7418-7426.
- 296 8. Stenberg-Hammar K, Hedlin G, Söderhäll C. Rhinovirus and preschool wheeze. Pediatric
297 Allergy and Immunology 2017;28:513-520.
- 298 9. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B.
299 Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc
300 Natl Acad Sci U S A 2005;102:12891-12896.
- 301 10. Brodzinski H, Ruddy RM. Review of new and newly discovered respiratory tract viruses
302 in children. Pediatr Emerg Care 2009;25:352-360; quiz 361-363.
- 303 11. Jartti T, Jartti L, Ruuskanen O, Söderlund-Venermo M. New respiratory viral infections.
304 Curr Opin Pulm Med 2012;18:271-278.
- 305 12. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus
306 isolated from young children with respiratory tract disease. Nat Med 2001;7:719-724.
- 307 13. van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus.
308 Nat Med 2004;10:368-373.
- 309 14. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in
310 China, 2019. N Engl J Med January 2020.

- 311 15. Hamre D, Procknow JJ. A new virus isolated from the human respiratory tract. Proc Soc
312 Exp Biol Med 1966;121:190-193.
- 313 16. McIntosh K, Becker WB, Chanock RM. Growth in suckling-mouse brain of 'IBV-like'
314 viruses from patients with upper respiratory tract disease. Proc Natl Acad Sci U S A
315 1967;58:2268-2273.
- 316 17. Peiris JSM, Lai ST, Poon LLM, et al. Coronavirus as a possible cause of severe acute
317 respiratory syndrome. Lancet 2003;361:1319-1325.
- 318 18. van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus.
319 Nat Med 2004;10:368-373.
- 320 19. Woo PCY, Lau SKP, Chu C -m., et al. Characterization and Complete Genome Sequence
321 of a Novel Coronavirus, Coronavirus HKU1, from Patients with Pneumonia. Journal of
322 Virology 2005;79:884-895.
- 323 20. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation
324 of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. New England
325 Journal of Medicine 2012;367:1814-1820.
- 326 21. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real
327 time. The Lancet Infectious Diseases 2020;20:533-534.
- 328 22. Centers for Reviews and Dissemination. CRD's Guidance for Undertaking Reviews in
329 301 Healthcare: Centers for Reviews and Dissemination. England: York Associates; 2009.
- 330 23. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic
331 Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009;6.
- 332 24. Hoy D, Brooks P, Woolf A, et al. Assessing risk of bias in prevalence studies: modification
333 of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012;65:934-
334 939.
- 335 25. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med
336 2002;21:1539-1558.
- 337 26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a
338 simple, graphical test. BMJ 1997;315:629-634.
- 339 27. Schwarzer G. meta: An R package for meta-analysis. R News 2007;7:40-5.
- 340 28. R Core Team. R: A language and environment for statistical computing. R Foundation for
341 Statistical Computing, Vienna, Austria. Available at <https://www.r-project.org/>. Accessed
342 28 September 2018.
- 343 29. Amat F, Henquell C, Verdan M, Roszyk L, Mulliez A, Labbé A. Predicting the severity
344 of acute bronchiolitis in infants: Should we use a clinical score or a biomarker?: Is a
345 Biomarker Useful in Acute Bronchiolitis? Journal of Medical Virology 2014;86:1944-
346 1952.

- 347 30. Antunes H, Rodrigues H, Silva N, et al. Etiology of bronchiolitis in a hospitalized pediatric
348 population: prospective multicenter study. *J Clin Virol* 2010;48:134-136.
- 349 31. Arabzadeh S a. M, Daeiparizi MH, Molaei HR, Aghaeiafshar A, Salari AA. The
350 Frequency Distribution of Parainfluenza, Adeno and Respiratory Syncytial Virus
351 Infections in Children below 2 Years Old with Bronchiolitis, by Multiplex Polymerase
352 Chain Reaction Method, Afzalipoor Hospital, Kerman, 2006. *Journal of Kerman*
353 *University of Medical Sciences* 2008;15:305-311.
- 354 32. Atay Ö, Pekcan S, Göktürk B, Özdemir M. Risk Factors and Clinical Determinants in
355 Bronchiolitis of Infancy. *Turk Thorac J* 2020;21:156-162.
- 356 33. Azkur D, Özaydın E, Dibek-Mısırlıoğlu E, et al. Viral etiology in infants hospitalized for
357 acute bronchiolitis. *Turk J Pediatr* 2014;56:592-596.
- 358 34. Bamberger E, Srugo I, Abu Raya B, et al. What is the clinical relevance of respiratory
359 syncytial virus bronchiolitis?: findings from a multi-center, prospective study. *European*
360 *journal of clinical microbiology & infectious diseases* : official publication of the
361 *European Society of Clinical Microbiology* 2012;31:3323-30.
- 362 35. Bekhof. Co-Infections in Children Hospitalised for Bronchiolitis: Role of Roomsharing.
363 *Journal of Clinical Medicine Research* 2013.
- 364 36. Bekhof J, Wessels M, Ten Velde E, et al. Room Sharing in Hospitalized Children With
365 Bronchiolitis and the Occurrence of Hospital-Acquired Infections: A Prospective Cohort
366 Study. *Hosp Pediatr* 2019;9:415-422.
- 367 37. Brand HK, de Groot R, Galama JMD, et al. Infection with multiple viruses is not
368 associated with increased disease severity in children with bronchiolitis. *Pediatric*
369 *Pulmonology* 2012;47:393-400.
- 370 38. Calvo C, Pozo F, García-García ML, et al. Detection of new respiratory viruses in
371 hospitalized infants with bronchiolitis: a three-year prospective study. *Acta Paediatr*
372 2010;99:883-887.
- 373 39. Cangiano G, Nenna R, Frassanito A, et al. Bronchiolitis: Analysis of 10 consecutive
374 epidemic seasons. *Pediatric pulmonology* 2016;51:1330-1335.
- 375 40. Chen Z-R, Ji W, Wang Y-Q, et al. Etiology of acute bronchiolitis and the relationship with
376 meteorological conditions in hospitalized infants in China. *Journal of the Formosan*
377 *Medical Association* 2014;113:463-469.
- 378 41. Dong-Keon YON, Chae-Yeon MIN, Eun-Kyo HA, et al. Clinical characteristics and
379 genetic variation in respiratory syncytial virus isolated from infants hospitalized due to
380 acute bronchiolitis in Korea during winter season 2016–2017. *Allergy, Asthma &*
381 *Respiratory Disease* 2018:110-115.
- 382 42. Dumas O, Mansbach JM, Jartti T, et al. A clustering approach to identify severe
383 bronchiolitis profiles in children. *Thorax* June 2016.
- 384 43. Ebihara T, Endo R, Ma X, Ishiguro N, Kikuta H. Detection of human coronavirus NL63
385 in young children with bronchiolitis. *Journal of medical virology* 2005;75:463-5.

- 386 44. Gökçe Ş, Kurugöl Z, Koturoğlu G, Çiçek C, Aslan A. Etiology, Seasonality, and Clinical
387 Features of Viral Respiratory Tract Infections in Children Hospitalized With Acute
388 Bronchiolitis: A Single-Center Study. *Glob Pediatr Health* 2017;4:2333794X17714378.
- 389 45. Hendaus MA, Alhammadi AH, Chandra P, Muneer E, Khalifa MS. Identifying agents
390 triggering bronchiolitis in the State of Qatar. *International journal of general medicine*
391 2018;11:143-149.
- 392 46. Janahi I, Abdulkayoum A, Almeshwesh F, Alkuwari M, Al Hammadi A, Alameri M. Viral
393 aetiology of bronchiolitis in hospitalised children in Qatar. *BMC Infect Dis* 2017;17:139.
- 394 47. Jartti T, Aakula M, Mansbach JM, et al. Hospital length-of-stay is associated with
395 rhinovirus etiology of bronchiolitis. *The Pediatric infectious disease journal* 2014;33:829-
396 34.
- 397 48. Mansbach JM, Hasegawa K, Henke DM, et al. Respiratory syncytial virus and rhinovirus
398 severe bronchiolitis are associated with distinct nasopharyngeal microbiota. *J Allergy Clin*
399 *Immunol* 2016;137:1909-1913.e4.
- 400 49. Mansbach JM, McAdam AJ, Clark S, et al. Prospective multicenter study of the viral
401 etiology of bronchiolitis in the emergency department. *Acad Emerg Med* 2008;15:111-
402 118.
- 403 50. Midulla F, Nenna R, Scagnolari C, et al. How Respiratory Syncytial Virus Genotypes
404 Influence the Clinical Course in Infants Hospitalized for Bronchiolitis. *The Journal of*
405 *infectious diseases* September 2018.
- 406 51. Midulla F, Scagnolari C, Bonci E, et al. Respiratory syncytial virus, human bocavirus and
407 rhinovirus bronchiolitis in infants. *Arch Dis Child* 2010;95:35-41.
- 408 52. Miller EK, Gebretsadik T, Carroll KN, et al. Viral Etiologies of Infant Bronchiolitis,
409 Croup and Upper Respiratory Illness During 4 Consecutive Years: *The Pediatric*
410 *Infectious Disease Journal* 2013;32:950-955.
- 411 53. Nascimento MS, de Souza AV, de Souza Ferreira AV, Rodrigues JC, Abramovici S, da
412 Silva Filho LVF. High Rate of Viral Identification and Coinfections in Infants with Acute
413 Bronchiolitis. *Clinics (Sao Paulo)* 2010;65:1133-1137.
- 414 54. Nenna R, Frassanito A, Petrarca L, Di Mattia G, Midulla F. Age Limit in Bronchiolitis
415 Diagnosis: 6 or 12 Months? *Front Pediatr* 2020;8:144.
- 416 55. Papadopoulos NG, Moustaki M, Tsofia M, et al. Association of rhinovirus infection with
417 increased disease severity in acute bronchiolitis. *Am J Respir Crit Care Med*
418 2002;165:1285-1289.
- 419 56. Papoff P, Moretti C, Cangiano G, et al. Incidence and predisposing factors for severe
420 disease in previously healthy term infants experiencing their first episode of bronchiolitis.
421 *Acta Paediatr* 2011;100:e17-23.
- 422 57. Petrarca L, Nenna R, Frassanito A, et al. Acute bronchiolitis: Influence of viral co-
423 infection in infants hospitalized over 12 consecutive epidemic seasons. *Journal of Medical*
424 *Virology* 2018;90:631-638.

- 425 58. Piedra F-A, Mei M, Avadhanula V, et al. The interdependencies of viral load, the innate
426 immune response, and clinical outcome in children presenting to the emergency
427 department with respiratory syncytial virus-associated bronchiolitis. *PLoS ONE*
428 2017;12:e0172953.
- 429 59. Pitrez PMC, Stein RT, Stuermer L, et al. [Rhinovirus and acute bronchiolitis in young
430 infants]. *J Pediatr (Rio J)* 2005;81:417-420.
- 431 60. Praznik A, Vinsek N, Prodan A. Risk factors for bronchiolitis severity: A retrospective
432 review of patients admitted to the university hospital from central region of Slovenia.
433 2018;12:765-771.
- 434 61. Ricart S, Rovira N, Garcia-Garcia JJ, et al. Frequency of apnea and respiratory viruses in
435 infants with bronchiolitis. *The Pediatric infectious disease journal* 2014;33:988-90.
- 436 62. Ricart S, Garcia-Garcia JJ, Anton A, et al. Analysis of Human Metapneumovirus and
437 Human Bocavirus Viral Load: *The Pediatric Infectious Disease Journal* 2013;32:1032-
438 1034.
- 439 63. Ricart S, Marcos MA, Sarda M, et al. Clinical risk factors are more relevant than
440 respiratory viruses in predicting bronchiolitis severity. *Pediatric Pulmonology*
441 2013;48:456-463.
- 442 64. Richard N, Komurian-Pradel F, Javouhey E, et al. The Impact of Dual Viral Infection in
443 Infants Admitted to a Pediatric Intensive Care Unit Associated with Severe Bronchiolitis:
444 *The Pediatric Infectious Disease Journal* 2008;27:213-217.
- 445 65. Robledo-Aceves M, Moreno-Peregrina MJ, Velarde-Rivera F, et al. Risk factors for severe
446 bronchiolitis caused by respiratory virus infections among Mexican children in an
447 emergency department. *Medicine* 2018;97:e0057.
- 448 66. Salvador Garcia C, Moreno Docon A, Pinero JA, Alfayate Miguelez S, Iborra Bendicho
449 MA. [Aetiology of bronchiolitis in hospitalised children in South-East Spain]. *Anales de*
450 *pediatria (Barcelona, Spain : 2003)* 2012;77:386-90.
- 451 67. Souza APD de, Leitão LA de A, Luisi F, et al. Lack of association between viral load and
452 severity of acute bronchiolitis in infants. *J Bras Pneumol* 2016;42:261-265.
- 453 68. Teeratakulpisarn J, Ekalaksananan T, Pientong C, Limwattananon C. Human
454 metapneumovirus and respiratory syncytial virus detection in young children with acute
455 bronchiolitis. *Asian Pacific journal of allergy and immunology* 2007;25:139-45.
- 456 69. Tsergouli K, Pappa S, Haidopoulou K, Gogou M, Giannopoulos A, Papa A. Respiratory
457 Syncytial Virus in Greece, 2016-2018. *Intervirology* 2019;62:210-215.
- 458 70. Tsou P, Vadivelan A, Kovvuri M, et al. Association between multiple respiratory viral
459 infections and pediatric intensive care unit admission among infants with bronchiolitis.
460 *Arch Pediatr* 2020;27:39-44.
- 461 71. Uyar M, Kuyucu N, Tezcan S, Aslan G, Tasdelen B. [Determination of the frequency of
462 human bocavirus and other respiratory viruses among 0-2 years age group children
463 diagnosed as acute bronchiolitis]. *Mikrobiyoloji bulteni* 2014;48:242-58.

- 464 72. Vieira SE, Thomazelli LM, de Paulis M, et al. Infections Caused by HRSV A ON1 Are
465 Predominant among Hospitalized Infants with Bronchiolitis in São Paulo City. *Biomed*
466 *Res Int* 2017;2017:3459785.
- 467 73. Wang Y, Ji W, Hao C, Yan YD, Shao X, Xu J. Comparison of bronchiolitis of human
468 metapneumovirus and human respiratory syncytial virus. *Acta virologica* 2015;59:98-100.
- 469 74. Wollmeister E, Alvarez AE, Bastos JCS, et al. Respiratory syncytial virus in Brazilian
470 infants - Ten years, two cohorts. *J Clin Virol* 2018;98:33-36.
- 471 75. Xepapadaki P, Psarras S, Bossios A, et al. Human Metapneumovirus as a causative agent
472 of acute bronchiolitis in infants. *J Clin Virol* 2004;30:267-270.
- 473 76. Xuan L, Rongfang Z, Zhiping XIE, Hanchun GAO, Zhaojun D, Donghai LIU. Clinical
474 characteristics of bocavirus infection in children with bronchiolitis. *Chinese Journal of*
475 *Experimental and Clinical Virology* 2018:187-190.
- 476 77. Yon D, Min C-Y, Ha EK, et al. Clinical characteristics and genetic variation in respiratory
477 syncytial virus isolated from infants hospitalized due to acute bronchiolitis in Korea during
478 winter season 2016–2017. 2018.
- 479 78. Zhou L, Xiao Q, Zhao Y, Huang A, Ren L, Liu E. The impact of viral dynamics on the
480 clinical severity of infants with respiratory syncytial virus bronchiolitis. *Journal of medical*
481 *virology* 2015;87:1276-84.
- 482 79. Fretzayas A, Moustaki M. Etiology and clinical features of viral bronchiolitis in infancy.
483 *World journal of pediatrics : WJP* 2017;13:293-299.
- 484 80. Meissner HC. Viral Bronchiolitis in Children. *New England Journal of Medicine*
485 2016;374:62-72.
- 486 81. Teshome G, Gattu R, Brown R. Acute bronchiolitis. *Pediatr Clin North Am* 2013;60:1019-
487 1034.
- 488 82. Heikkinen T, Järvinen A. The common cold. *The Lancet* 2003;361:51–59.
- 489 83. Ginocchio CC. Detection of respiratory viruses using non-molecular based methods. *J*
490 *Clin Virol* 2007;40 Suppl 1:S11-14.
- 491 84. Rylander E, Eriksson M, Pershagen G, Nordvall L, Ehrnsr A, Ziegler T. Wheezing
492 bronchitis in children. Incidence, viral infections, and other risk factors in a defined
493 population. *Pediatric allergy and immunology* 1996;7:6–11.
- 494 85. Gern JE, Busse WW. The role of viral infections in the natural history of asthma. *Journal*
495 *of Allergy and Clinical Immunology* 2000;106:201-212.
- 496 86. Pattermore PK, Johnston SL, Bardin PG. Viruses as precipitants of asthma symptoms. I.
497 *Epidemiology. Clinical & Experimental Allergy* 1992;22:325-336.
- 498 87. Berezin EN. Rhinovirus and bronchiolitis. *Jornal de pediatria* 2006;82:163; author reply
499 164.

- 500 88. Drysdale SB, Mejias A, Ramilo O. Rhinovirus - not just the common cold. *J Infect* 2017;74
501 Suppl 1:S41-S46.
- 502 89. Korppi M. Rhinovirus bronchiolitis: to be or not to be? *Acta Paediatrica* 2014;103:997-
503 999.
- 504 90. Lau, SKP SK, Yip, Yip CCY CC, Woo, Woo PCY PC, Yuen K-Y. Human rhinovirus C:
505 a newly discovered human rhinovirus species. *Emerg Health Threats J* 2010;3.
- 506 91. McErlean P, Shackelton LA, Lambert SB, Nissen MD, Sloots TP, Mackay IM.
507 Characterisation of a newly identified human rhinovirus, HRV-QPM, discovered in
508 infants with bronchiolitis. *J Clin Virol* 2007;39:67-75.
- 509 92. Renwick N, Schweiger B, Kapoor V, et al. A Recently Identified Rhinovirus Genotype Is
510 Associated with Severe Respiratory-Tract Infection in Children in Germany. *J Infect Dis*
511 2007;196:1754-1760.
- 512 93. Zheng X-Y, Xu Y-J, Guan W-J, Lin L-F. Regional, age and respiratory-secretion-specific
513 prevalence of respiratory viruses associated with asthma exacerbation: a literature review.
514 *Arch Virol* 2018;163:845-853.
- 515 94. Liu L, Pan Y, Zhu Y, et al. Association between rhinovirus wheezing illness and the
516 development of childhood asthma: a meta-analysis. *BMJ Open* 2017;7:e013034.
- 517 95. Cox DW, Bizzantino J, Ferrari G, et al. Human rhinovirus species C infection in young
518 children with acute wheeze is associated with increased acute respiratory hospital
519 admissions. *American journal of respiratory and critical care medicine* 2013;188:1358-64.
- 520 96. Halmo Hurdum S, Zhang G, Khoo SK, et al. Recurrent rhinovirus detections in children
521 following a rhinovirus-induced wheezing exacerbation: A retrospective study.
522 *International journal of pediatrics and child health* 2015;3:10-18.
- 523 97. Turunen R, Koistinen A, Vuorinen T, et al. The first wheezing episode: respiratory virus
524 etiology, atopic characteristics, and illness severity. *Pediatr Allergy Immunol*
525 2014;25:796-803.
- 526 98. van der Zalm MM, Uiterwaal CSPM, Wilbrink B, Koopman M, Verheij TJM, van der Ent
527 CK. The influence of neonatal lung function on rhinovirus-associated wheeze. *Am J*
528 *Respir Crit Care Med* 2011;183:262-267.
- 529 99. Broccolo F, Falcone V, Esposito S, Toniolo A. Human bocaviruses: Possible etiologic role
530 in respiratory infection. *J Clin Virol* 2015;72:75-81.
- 531 100. Chow BDW, Esper FP. The human bocaviruses: a review and discussion of their role in
532 infection. *Clin Lab Med* 2009;29:695-713.
- 533 101. Christensen A, Nordbø SA, Krokstad S, Rognlien AGW, Døllner H. Human bocavirus
534 commonly involved in multiple viral airway infections. *Journal of Clinical Virology*
535 2008;41:34-37.

- 536 102. García-García ML, Calvo C, Pozo F, et al. Human bocavirus detection in nasopharyngeal
537 aspirates of children without clinical symptoms of respiratory infection. *Pediatr Infect Dis*
538 *J* 2008;27:358-360.
- 539 103. Kahn J. Human bocavirus: clinical significance and implications. *Curr Opin Pediatr*
540 2008;20:62-66.
- 541 104. Schildgen O, Müller A, Allander T, et al. Human Bocavirus: Passenger or Pathogen in
542 Acute Respiratory Tract Infections? *Clin Microbiol Rev* 2008;21:291-304.
- 543 105. Edner N, Castillo-Rodas P, Falk L, Hedman K, Söderlund-Venermo M, Allander T. Life-
544 threatening respiratory tract disease with human bocavirus-1 infection in a 4-year-old
545 child. *J Clin Microbiol* 2012;50:531-532.
- 546 106. Ursic T, Steyer A, Kopriva S, Kalan G, Krivec U, Petrovec M. Human Bocavirus as the
547 Cause of a Life-Threatening Infection. *Journal of Clinical Microbiology* 2011;49:1179-
548 1181.
- 549 107. Christensen A, Kesti O, Elenius V, et al. Human bocaviruses and paediatric infections.
550 *Lancet Child Adolesc Health* April 2019.
- 551 108. Jacobs SE, Lamson DM, St. George K, Walsh TJ. Human Rhinoviruses. *Clin Microbiol*
552 *Rev* 2013;26:135-162.
- 553 109. Dick EC, Jennings LC, Mink KA, Wartgow CD, Inhorn SL. Aerosol transmission of
554 rhinovirus colds. *J Infect Dis* 1987;156:442-448.
- 555 110. Gwaltney JM, Moskalski PB, Hendley JO. Hand-to-hand transmission of rhinovirus colds.
556 *Ann Intern Med* 1978;88:463-467.
- 557 111. Hall CB, Douglas RG. Modes of transmission of respiratory syncytial virus. *J Pediatr*
558 1981;99:100-103.
- 559 112. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory Syncytial Virus
560 Seasonality: A Global Overview. *J Infect Dis* January 2018.
- 561 113. Haas LEM, Thijsen SFT, van Elden L, Heemstra KA. Human Metapneumovirus in Adults.
562 *Viruses* 2013;5:87-110.
- 563 114. Hermos CR, Vargas SO, McAdam AJ. Human Metapneumovirus. *Clinics in Laboratory*
564 *Medicine* 2010;30:131-148.
- 565 115. Rogers E, Greaves K, Paul SP. A clinical companion to the NICE guide on bronchiolitis.
566 *Nurs Child Young People* 2017;29:14-16.
- 567 116. Bordley W, Viswanathan M, King VJ, et al. Diagnosis and testing in bronchiolitis: A
568 systematic review. *Arch Pediatr Adolesc Med* 2004;158:119-126.
- 569 117. Stollar F, Alcoba G, Gervaix A, Argiroffo CB. Virologic testing in bronchiolitis: does it
570 change management decisions and predict outcomes? *European journal of pediatrics*
571 2014;173:1429-35.

- 572 118. Brand HK, de Groot R, Galama JMD, et al. Infection with multiple viruses is not
573 associated with increased disease severity in children with bronchiolitis. *Pediatric*
574 *Pulmonology* 2012;47:393-400.
- 575 119. Sly PD, Jones CM. Viral co-detection in infants hospitalized with respiratory disease: is it
576 important to detect? *J Pediatr (Rio J)* 2011;87:277-280.
- 577 120. Ferronato A, Gilio A, Ferraro A, Paulis M, Vieira S. Etiological diagnosis reduces the use
578 of antibiotics in infants with bronchiolitis. *Clinics* 2012;67:1007-1011.
- 579 121. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis,
580 management, and prevention of bronchiolitis. *Pediatrics* 2014;134:e1474-1502.
- 581 122. Noor A, Krilov LR. Respiratory syncytial virus vaccine: where are we now and what
582 comes next? *Expert Opin Biol Ther* November 2018:1-10.
- 583 123. Hancock DG, Charles-Britton B, Dixon D-L, Forsyth KD. The heterogeneity of viral
584 bronchiolitis: A lack of universal consensus definitions. *Pediatr Pulmonol* 2017;52:1234-
585 1240.

586

587

588

589

590

591

592


593

594

595


596 Fig 1. Flow chart of research and selection of studies

597



617 Fig 2. Global prevalence of Respiratory Viruses in children with bronchiolitis

618



619